Founded in 2017, the proteomics company Seer (Nasdaq:SEER) is building up a growing roster of customers, including pharma and biotech companies, translational and academic labs and CROs. Applications of its technology include biomarker discovery, target identification and multiomics research for cancer or other complex disease detection. Recently, Weill Cornell Medicine and privately-held SpaceX used Seer’s…
How Mission Bio is working to drive precision medicine
Mission Bio (San Francisco) is a growth-stage company spun out of the microfluidics lab at the University of California San Francisco (UCSF) in 2014. “We have been commercial since late 2017,” said the company’s CEO, Yan Zhang, in a recent interview. Initially focusing on oncology, Mission Bio has cast its gaze across precision medicine to…
Janssen’s company group chairman dishes on growth strategy
In 2021, Johnson & Johnson’s (NYSE:JNJ) pharmaceutical segment Janssen reported revenue of more than $50 billion in fiscal 2021 and operational growth of 13.1%. Janssen’s pathway approach could fuel future growth. Janssen exec Tom Cavanaugh‘s next big goal for Janssen is ensure Janssen is a $60 billion pharmaceutical company by 2025. Heavy reliance on R&D will…
How Karius aims to transform the diagnosis of infections with a non-invasive liquid biopsy
The startup Karius aims to help establish a world where infectious disease is no longer a major threat to human health. “It’s an audacious vision,” said Dr. Brad Perkins, chief medical officer at Karius. “But I think it’s commensurate with the platform we’ve developed and continue to evolve.” The Redwood City, California-based company has developed…
How Cellares aims to transform cell therapy manufacturing
The startup Cellares has a mission to enable industrial-scale cell therapy manufacturing with its Cell Shuttle, which it dubs a “factory in a box.” The germ for the idea traces back to market research that South San Francisco, California-based Cellares co-founder and CEO Fabian Gerlinghaus focused on in a prior role. While attending industry conferences,…